Skip to main content

Day: September 1, 2020

1847 Holdings Announces Special Share Dividend of 1847 Goedeker Stock

Written by Customer Service on . Posted in Dividend Reports And Estimates.

NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) — 1847 Holdings LLC (OTCQB: EFSH) (the “Company”), a publicly traded acquisition holding company platform that combines the attractive attributes of private, lower-middle market businesses with the liquidity and transparency of a publicly traded company, today announced its proposed special dividend of 3.325 million shares of 1847 Goedeker (NYSE American: GOED) common stock to the Company’s shareholders.“The IPO of Goedeker’s is a major milestone for 1847 Holdings and demonstrates our ability to generate returns for our shareholders through realized capital appreciation of our operating subsidiaries,” commented Ellery W. Roberts, CEO of 1847 Holdings.The record date for the dividend and the distribution date have not yet been set. 1847 Holdings intends to distribute all of the 3.325 million...

Continue reading

Indiva Reports Record Second Quarter Fiscal Year 2020 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

LONDON, Ontario, Sept. 01, 2020 (GLOBE NEWSWIRE) — Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF), a leading Canadian producer of cannabis edibles and other cannabis products, is pleased to announce its financial and operating results for second quarter fiscal 2020 ended June 30, 2020. All figures are reported in Canadian dollars ($), unless otherwise indicated. Indiva’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). For a more comprehensive overview of the corporate and financial highlights presented in this press release, please refer to Indiva’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three and Six Months Ended June 30, 2020, and the Company’s Condensed Consolidated Interim Financial Statements...

Continue reading

TrackX Reports Third Quarter of Fiscal 2020

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

DENVER, Sept. 01, 2020 (GLOBE NEWSWIRE) — TrackX Holdings Inc. (TSX.V:TKX | OTC: TKXHF | FRANKFURT:3TH) (“TrackX” or the “Company), a Software-as-a-Service (SaaS)-based enterprise asset management solution provider, announces the financial and operational highlights from its third quarter of fiscal 2020 ended June 30, 2020. All results are reported in Canadian dollars unless otherwise specified. A complete set of the June 30, 2020 Consolidated Financial Statements and Management’s Discussion & Analysis has been filed on SEDAR (www.sedar.com).Financial Highlights for the 3-Months Ended June 30, 2020Gross margin of 69%, versus 39% for the same quarter last year;Recurring revenue decreased by 47% over the previous year period to $402,492 due the reduction in yard management revenue resulting from the sale of that line of business...

Continue reading

FibroGen to Present at Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:Citigroup 15th Annual BioPharma Conference on September 9, 2020 at 2:25 PM Eastern TimeMorgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020 at 3:30 PM Eastern TimeA live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at https://fibrogen.gcs-web.com/.  A replay will be available for approximately 30 days.About FibroGenFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible...

Continue reading

Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer

Written by Customer Service on . Posted in Public Companies.

NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Alexis Pinto as Chief Legal Officer. Ms. Pinto joins Zentalis with over 20 years of legal and strategic business development experience in the healthcare industry, most recently at Celgene Corporation.“We are thrilled to welcome Alexis to Zentalis, as her depth of knowledge in deal-making and leading legal teams within the life science sector will be a great asset to the Company,” said Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. “Alexis will be responsible for the legal function across the organization,...

Continue reading

Form 8.3 – Modern Water Plc

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

Continue reading

Ansys CFO to Present at CITI 2020 Global Technology Conference

Written by Customer Service on . Posted in Public Companies.

PITTSBURGH, Sept. 01, 2020 (GLOBE NEWSWIRE) — ANSYS, Inc. (NASDAQ: ANSS), announced today that Maria Shields, Senior Vice President, CFO and Annette Arribas, Senior Director, Global Investor Relations will virtually participate in a moderated discussion at the CITI 2020 Global Technology Conference on September 9th at 8:55 a.m. ET.A live audio webcast and archive of the presentation will be available at: https://investors.ansys.com/events-and-presentations/events-calendar/default.aspx/ Forward-Looking StatementsStatements made on the webcast are as of the date of the webcast and Ansys does not assume any obligation to update any statements made live or the archived webcast. Matters discussed may include forward-looking statements about Ansys’s anticipated financial results and growth, as well as about the development of products...

Continue reading

Form 8.3 – Integumen Plc

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

Continue reading

MediPharm Labs Enters Denmark Medical Cannabis Market, Secures New White-Label Supply Customers

Written by Customer Service on . Posted in Public Companies.

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it will supply cannabis concentrate products in Denmark to two new medical cannabis customers under two separate white-label agreements.  These customers will be serviced by both GMP approved facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ first supply agreements for the export of finished products to Denmark. Denmark granted patients legal access to cannabis-based medicinal products two years ago as part of a four-year pilot program. The program provides patients with safe...

Continue reading

Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial

Written by Customer Service on . Posted in Public Companies.

BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced dosing of the first three patients in its new Phase 2a clinical trial targeting early AD and PD patients.The two-part study, which received IRB approval in July 2020, is designed to treat a combined total of 28 AD and PD patients for four weeks with Annovis’ lead compound, ANVS401. The study compares in both patient populations how nerve cells die by measuring all the steps in the toxic cascade leading to nerve cell death and how ANVS401 might reverse the toxic cascade and recover normal brain function. In addition to target and pathway engagement, the Phase 2a study also examines safety...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.